Literature DB >> 17056516

Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide.

Dorit Fabricius1, M Sue O'Dorisio, Sue Blackwell, Bernd Jahrsdörfer.   

Abstract

Plasmacytoid dendritic cells (PDC) are considered the main sentinels against viral infections and play a major role in immune tolerance. Vasoactive intestinal peptide (VIP) is a potent immunomodulator, whose role in PDC function is unknown. The present study was designed to investigate whether human PDC express VIP receptors and whether VIP has immunological effects on PDC. Using real-time RT-PCR and immunofluorescence, we demonstrated that VIP receptors VPAC1 and VPAC2 are expressed on PDC. After culturing PDC with VIP and CpG oligodeoxynucleotides for 48 h, expression of surface molecules with significance for PDC-T cell interactions as well as IFN-alpha secretion were quantified using FACS analysis and ELISA, respectively. For functional assays, CFSE-stained CD4+ T cells were coincubated with differentially treated PDC. T cell proliferation and production of various cytokines were determined by FACS analysis and ELISA. VIP enhanced PDC expression of CD86, MHC II, and CCR7. In contrast, VIP inhibited PDC secretion of IFN-alpha and expression of Neuropilin-1 and MHC I. The potential of CpG oligodeoxynucleotide-activated PDC to induce proliferation of allogeneic CD4(+) T cells was impaired when VIP was present during activation. Furthermore, pretreatment of PDC with VIP resulted in a decrease of the IFN-gamma:IL-4 ratio in cocultured T cells, suggesting a modulation of the immune response toward Th2. Taken together, these results strongly suggest that VIP regulates the immunological function of human PDC. VIP may thus be involved in the modulation of immune responses to viral infections as well as in the maintenance of immune tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056516     DOI: 10.4049/jimmunol.177.9.5920

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Vasoactive intestinal peptide increases hepatic transduction and reduces innate immune response following administration of helper-dependent Ad.

Authors:  Francesco Vetrini; Nicola Brunetti-Pierri; Donna J Palmer; Terry Bertin; Nathan C Grove; Milton J Finegold; Philip Ng
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

2.  Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion.

Authors:  Bernd Jahrsdörfer; Angelika Vollmer; Sue E Blackwell; Julia Maier; Kai Sontheimer; Thamara Beyer; Birgit Mandel; Oleg Lunov; Kyrylo Tron; G Ulrich Nienhaus; Thomas Simmet; Klaus-Michael Debatin; George J Weiner; Dorit Fabricius
Journal:  Blood       Date:  2009-12-03       Impact factor: 22.113

3.  Breaking human cytomegalovirus major immediate-early gene silence by vasoactive intestinal peptide stimulation of the protein kinase A-CREB-TORC2 signaling cascade in human pluripotent embryonal NTera2 cells.

Authors:  Jinxiang Yuan; Xiaoqiu Liu; Allen W Wu; Patrick W McGonagill; Michael J Keller; Courtney S Galle; Jeffery L Meier
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

Review 4.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

5.  Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages.

Authors:  Juan Luis Herrera; Elena Gonzalez-Rey; Rafael Fernandez-Montesinos; Francisco J Quintana; Rafael Najmanovich; David Pozo
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310

6.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

Review 7.  Disease-Associated Plasmacytoid Dendritic Cells.

Authors:  Shuang Li; Jing Wu; Shan Zhu; Yong-Jun Liu; Jingtao Chen
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 8.  Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Authors:  Matilde Monti; Francesca Consoli; Raffaella Vescovi; Mattia Bugatti; William Vermi
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

Review 9.  Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.

Authors:  Dóra Bencze; Tünde Fekete; Kitti Pázmándi
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

Review 10.  The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle.

Authors:  Sandra De Keijzer; Marjolein B M Meddens; Ruurd Torensma; Alessandra Cambi
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.